"End of Day Report" author: Sees no possibility for the stock market to stop falling in the short term
BlockBeats News, on March 19, Citrini Research, author of the "End Times Report," posted about the recent market trends, stating that they really see no possibility for the stock market not to continue falling in the short term.
The market has been so desperate for "good news" that people have started making it up themselves, forgetting that in an actual war, both sides must agree to end it (or one side must surrender). Eventually, they will realize this.
The Fed's rate-cutting cycle is being fully absorbed by the market. Two weeks ago, SOFR Z7 (Secured Overnight Financing Rate futures) was 75 basis points lower than in March 2026. Now it has dropped to 25 basis points, and the IOR (Interest on Reserve Balances) remains firmly above the two-year yield (which means reserve managers do not expect the rate-cutting cycle to continue, so they are not buying during the decline). If the non-farm payroll data is strong, it will hit the rates market hard (just as financing is becoming increasingly important for the world's largest companies); and if the data is weak, I don't think the stock market will react positively either.
All of this is happening at a time when AI may not be convincing enough for companies to replace workers with machines under normal operations, but it is definitely sufficient for companies to try using it to fill positions that have been cut due to economic pressures—and they may discover they no longer need to rehire for these roles.
Seeing some bearish scenarios and then dismissively saying "it's already priced in" is one thing; this has always been a good strategy (most years usually see a 10-15% pullback), but keep in mind that the S&P 500 is currently only about 5% off its all-time high.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly

XRP Ledger adds account control feature, enabling enterprises to manage assets offline.

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
